Gloftrinid (Bortezomib)

Gloftrinid is indicated for the treatment of certain hematologic malignancies, primarily in patients who have not responded adequately to prior therapy. It is prescribed as part of combination regimens to improve disease control and prolong survival.

• Treatment of newly diagnosed multiple myeloma in combination with dexamethasone and immunomodulatory agents.
• Therapy for relapsed or refractory multiple myeloma after prior lines of treatment.
• Management of mantle cell lymphoma in patients unsuitable for stem‑cell transplantation.
• Use in clinical trials evaluating bortezomib‑based regimens for other B‑cell malignancies.

Like other proteasome inhibitors, Gloftrinid may cause a range of adverse effects that vary in frequency and severity.

Common

• Fatigue or weakness.
• Nausea, vomiting, or loss of appetite.
• Diarrhea or constipation.
• Peripheral neuropathy (tingling or numbness in hands/feet).
• Low blood cell counts (anemia, neutropenia, thrombocytopenia).

Serious

• Severe allergic reactions (anaphylaxis, rash, fever).
• Cardiac arrhythmias or heart failure.
• Pulmonary toxicity (interstitial lung disease).

Before initiating Gloftrinid, clinicians assess patient-specific factors and monitor for conditions that could increase the risk of complications.

• Baseline and periodic evaluation of blood counts and liver function tests.
• Assessment for pre‑existing peripheral neuropathy; dose adjustments may be needed.
• Screening for hepatitis B and C, as reactivation can occur.
• Caution in patients with cardiac disease or uncontrolled hypertension.
• Avoid use during pregnancy; discuss contraception with women of childbearing potential.
• Monitor for signs of infection, especially febrile neutropenia.
• Adjust dosing in patients with severe renal impairment.

Gloftrinid can interact with other medicines, influencing its efficacy or safety profile, so careful review of concomitant drugs is essential.

Avoid

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce bortezomib exposure.
• Live vaccines during treatment due to immunosuppression.

Use with caution

• Anticoagulants (warfarin, DOACs) because of increased bleeding risk.
• Other neurotoxic agents (e.g., vincristine) that may exacerbate peripheral neuropathy.
• Concomitant use of other proteasome inhibitors or investigational agents.